On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.